Presentations

  • Utilizing Multiomic Advanced Diagnostics to Identify CDK4/6 inhibitor Response Predictors and a Post-treatment Multiomic Signature for Patients with ER+/HER2- Metastatic Breast Cancer (SIDEOUT-3)
    Abu-Khalaf M, Pierobon M, Denduluri N, aldes-Albini F, Forero-Torres A, Clark A, Yung R, Mita M, Christensen S, Awerkamp K, Murphy R, Hatzis C, Zelterman D, Liotta L, Petricoin EF. San Antonio Breast Cancer Symposium 2018, San Antonio, TX. (READ)
  • Multi-omic profiling of metastatic lesions to guide treatment selection: the Side Out 2 trial experience
    Pierobon M, Robert N, Northfelt DW, Jahanzeb M, Wong S, Hodge KA, Aldrich J, Craig DW, Liotta L, Wulfkuhle J, Gallager RI, Arguello D, Conrad A, Kemkes A, Loesch D, Vocila L, Dunetz B, Carpten JD, Petricoin EF, Anthony SP. ASCO annual meeting, 2018, Chicago, IL. (READ)
  • PD-L1 expression differs across cancer metastatic sites from breast tumors
    Pierobon M, Hodge KA, Baldelli E, Anthony SP, Robert N, Northfelt DW, Jahanzeb M, Vocila L, Liotta L, Dunetz B, Petricoin EF. AACR annual meeting, 2018, Chicago, IL. (READ)
  • The Side Out Foundation Metastatic Breast Cancer Database, an open-access portal for “multi-omics” molecular data and more
    Baldelli E, Ghaemi S, Avramovic S, Wojtusiak J, Liotta LA, Alemi F, Petricoin E, Dunetz B, Pierobon M. AACR annual meeting, 2018, Chicago, IL. (READ)
  • Androgen receptor (AR) activation in breast cancer (BC) liver metastases
    Ramos C, Hoke NN, Wilks T, Levin MK, Hippely S, Pierobon M, Petricoin EF, O’Shaughnessy J. ASCO Annual meeting 2017, Chicago, IL. (READ)
  • Quantitative measurement of PD-L1 expression across tumor types using laser capture microdissection and reverse phase protein 
    Citation: Baldelli E, Calvert V, Hodge KA, Sereni MI, Gambara G, Haura E, Crino’ L, Dunetz B, Pecorelli S, Perry D, Anthony SP, Robert N, Northfelt DW, Jahanzeb M, Petricoin EF, Pierobon M. AACR Annual meeting 2017, Washington DC. (READ)
  • A multi-omic analysis to explore the impact of “actionable” genomic alterations on protein pathway activation: clinical implication for precision medicine in metastatic breast cancer
    Pierobon M, Wong S, Reeder A, Anthony SP, Robert N, Northfelt DW, Jahanzeb M, Vocila L, Wulfkuhle J, Dunetz B, Aldrich J, Byron S, Craig D, Liotta L, Carpten JD, Petricoin EF. San Antonio Breast Cancer Symposium 2016, San Antonio, TX. (READ)
  • Predictive value of topoisomerase 1 by immunohistochemistry (top1 IHC) in patients with metastatic breast cancer receiving irinotecan-based therapy
    Robert NJ, Anthony SP, Arguello D, Jameson GS, Northfelt DW, Jahanzeb M, Petricoin E, Pierobon M, Dunetz B, Liotta LA, Loesch DM. ASCO Annual meeting 2016, Chicago, IL. (READ)
  • Androgen receptor activation in HER2-negative breast cancer liver metastases
    Ramos C, Pierobon M, Hoke NH, Liotta L, Al-Hader A, Levin MK, Dunetz B, O’Shaughnessy J, Petricoin E. ASCO Annual meeting 2016, Chicago, IL. (READ)
  • The AKT-mTOR pathwat as a potential organ-specific drug target signature of hepatic metastases from breast cancer
    Pierobon M, Wong S, Reeder A, Anthony SP, Robert N, Northfelt DW, Jahanzeb M, Vocila L, Wulfkuhle J, Dunetz B, Aldrich J, Byron S, Craig D, Liotta L, Petricoin EF, Carpten JD. San Antonio Breast Cancer Symposium 2015, San Antonio, TX. (READ)
  • Pathway activation mapping of metastatic breast cancer identifies potential organ-specific signatures: implications for patient stratification to targeted treatment
    Pierobon M, Anthony SP, Reeder A, Robert N, Northfelt D, Jahanzeb M, Vocila L, Wulfkuhle J, Dunetz B, Liotta L, Petricoin E.F. San Antonio Breast Cancer Symposium 2014, San Antonio, TX. (READ)
  • Protein Pathway Activation Mapping Analysis of Metastatic Breast Cancer Reveals Potential New Targets for Personalized Therapy
    Pierobon M, Reeder A, Anthony S, Jameson G, Robert N, Sachdev J, Vocila L, Wulfkuhle J, Baldelli E, Liotta L, Petricoin E. AACR Annual meeting 2013, Washington DC. (READ)
  • A pilot study utilizing molecular profiling to find potential targets and select individualized treatments for patients with metastatic breast cancer
    Jameson G, Petricoin E, Sachdev J, Liotta L, Loesch D, Anthony S, Chadha M, Pierobon M, Reeder K, Fulk M, Vocila L, Cantafio N, Dunetz B, Robert N.  ASCO Annual meeting 2013, Chicago, IL. (READ)